BTIG analyst Mark Massaro lowered the firm’s price target on NeoGenomics (NEO) to $18 from $21 and keeps a Buy rating on the shares. The stock fell 20% following the “surprise announcement ...

Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).

When Mark Massaro started his career 35 years ago with Orange County Public Works, the department dispatched road graders once a week to work on lumpy dirt roads. “Every time it rained ...

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud at the company. Shares were down about 4%, and BTIG ...